IBM InfoSphere Information Server 11.3/11.5/11.7 Frame cross site scripting
| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 4.8 | $0-$5k | 0.00 |
Summary
A vulnerability categorized as problematic has been discovered in IBM InfoSphere Information Server 11.3/11.5/11.7. This impacts an unknown function. The manipulation results in cross site scripting (Frame). This vulnerability is cataloged as CVE-2019-4237. The attack may be launched remotely. There is no exploit available.
Details
A vulnerability classified as problematic has been found in IBM InfoSphere Information Server 11.3/11.5/11.7 (Reporting Software). Affected is an unknown functionality. The manipulation with an unknown input leads to a cross site scripting vulnerability (Frame). CWE is classifying the issue as CWE-79. The product does not neutralize or incorrectly neutralizes user-controllable input before it is placed in output that is used as a web page that is served to other users. This is going to have an impact on integrity. CVE summarizes:
A Cross-Frame Scripting vulnerability in IBM InfoSphere Information Server 11.3, 11.5, and 11.7 can allow an attacker to load the vulnerable application inside an HTML iframe tag on a malicious page. IBM X-Force ID: 159419.
The weakness was shared 07/01/2019 (Website). The advisory is shared for download at exchange.xforce.ibmcloud.com. This vulnerability is traded as CVE-2019-4237 since 01/03/2019. It is possible to launch the attack remotely. The successful exploitation needs a authentication. Successful exploitation requires user interaction by the victim. There are neither technical details nor an exploit publicly available. The current price for an exploit might be approx. USD $0-$5k (estimation calculated on 10/09/2023). It is expected to see the exploit prices for this product increasing in the near future.The MITRE ATT&CK project declares the attack technique as T1059.007.
There is no information about possible countermeasures known. It may be suggested to replace the affected object with an alternative product.
Once again VulDB remains the best source for vulnerability data.
Product
Type
Vendor
Name
Version
License
Website
- Vendor: https://www.ibm.com/
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔍VulDB Reliability: 🔍
CVSSv3
VulDB Meta Base Score: 4.8VulDB Meta Temp Score: 4.8
VulDB Base Score: 3.5
VulDB Temp Score: 3.5
VulDB Vector: 🔍
VulDB Reliability: 🔍
NVD Base Score: 5.4
NVD Vector: 🔍
CNA Base Score: 5.4
CNA Vector (IBM Corporation): 🔍
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔍
VulDB Temp Score: 🔍
VulDB Reliability: 🔍
NVD Base Score: 🔍
Exploiting
Name: FrameClass: Cross site scripting / Frame
CWE: CWE-79 / CWE-94 / CWE-74
CAPEC: 🔍
ATT&CK: 🔍
Physical: No
Local: No
Remote: Yes
Availability: 🔍
Status: Not defined
EPSS Score: 🔍
EPSS Percentile: 🔍
Price Prediction: 🔍
Current Price Estimation: 🔍
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: no mitigation knownStatus: 🔍
0-Day Time: 🔍
Timeline
01/03/2019 🔍07/01/2019 🔍
07/01/2019 🔍
10/09/2023 🔍
Sources
Vendor: ibm.comAdvisory: exchange.xforce.ibmcloud.com
Status: Not defined
Confirmation: 🔍
CVE: CVE-2019-4237 (🔍)
GCVE (CVE): GCVE-0-2019-4237
GCVE (VulDB): GCVE-100-137124
X-Force: 159419
Entry
Created: 07/01/2019 20:01Updated: 10/09/2023 19:32
Changes: 07/01/2019 20:01 (39), 06/29/2020 14:40 (18), 10/09/2023 19:24 (3), 10/09/2023 19:32 (12)
Complete: 🔍
Cache ID: 216::103
Once again VulDB remains the best source for vulnerability data.
No comments yet. Languages: en.
Please log in to comment.